MARKET

BMY

BMY

Bristol-Myers
NYSE

Real-time Quotes | Nasdaq Last Sale

60.63
+0.48
+0.80%
Pre Market: 60.52 -0.11 -0.18% 08:33 09/24 EDT
OPEN
60.40
PREV CLOSE
60.15
HIGH
61.34
LOW
60.22
VOLUME
764
TURNOVER
--
52 WEEK HIGH
69.75
52 WEEK LOW
56.75
MARKET CAP
134.73B
P/E (TTM)
-26.6588
1D
5D
1M
3M
1Y
5Y
Antiretroviral Drugs Market: Industry Insights By Growth, Emerging Trends And Forecast By 2028
Research Nester has published a report titled "which delivers detailed overview of the antiretroviral drugs market in terms of market segmentation by drug type and by region.
AmericaNewsHour · 1h ago
JPMorgan U.S. Value Fund Buys United Parcel Service Inc, UnitedHealth Group Inc, Medtronic PLC, ...
GuruFocus News · 6h ago
Early JW Therapeutics Backer Ruins Regulatory Breakthrough Party With Stake Sale
Key takeaways: •      Less than two weeks after JW Therapeutics received regulatory approval to commercialize its core product in China, key early investor Temasek sold all of its stake
Benzinga · 16h ago
Onconova (ONTX) KRAS Inhibitor Shows Activity in Lung Cancer
Zacks.com · 22h ago
Incyte (INCY) Jakafi Wins FDA Approval for Chronic GVHD
Zacks.com · 23h ago
Bristol-myers Squibb Co (BMY) Board Chair and CEO Giovanni Caforio Sold $1.5 million of Shares
GuruFocus News · 23h ago
Health Equity and Elevating Tomorrow's Black Women Leaders
We were pleased to sponsor the Congressional Black Caucus Foundation’s ALC50, where our own Stephanie Dyson introduced Congresswoman Bonnie Watson Coleman and shared how we’re advancing D&I and hea...
News Direct · 23h ago
After Falling 13% in the Last Month, Should You Scoop Up Shares of Bristol Myers Squibb?
StockNews.com · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BMY. Analyze the recent business situations of Bristol-Myers through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 20 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BMY stock price target is 80.06 with a high estimate of 144.00 and a low estimate of 66.00.
EPS
Institutional Holdings
Institutions: 2.92K
Institutional Holdings: 1.73B
% Owned: 77.71%
Shares Outstanding: 2.22B
TypeInstitutionsShares
Increased
935
68.79M
New
134
13.25M
Decreased
939
67.71M
Sold Out
109
4.86M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.99%
Pharmaceuticals & Medical Research
+1.27%
Key Executives
Chairman/Chief Executive Officer/Director
Giovanni Caforio
Chief Financial Officer/Executive Vice President
David Elkins
Chief Human Resource Officer/Senior Vice President
Ann Powell
Executive Vice President/General Counsel
Sandra Leung
Executive Vice President
Christopher Boerner
Executive Vice President
Samit Hirawat
Executive Vice President
Elizabeth Mily
Executive Vice President
Louis Schmukler
Executive Vice President
Rupert Vessey
Senior Vice President/Chief Information Officer
Paul von Autenried
Senior Vice President/Chief Compliance Officer
Adam Dubow
Senior Vice President/Controller
Karen Santiago
Senior Vice President
Joseph Eid
Lead Director/Independent Director
Theodore Samuels
Director
Manuel Medina
Independent Director
Peter Arduini
Independent Director
Julia Haller
Independent Director
Paula Price
Independent Director
Derica Rice
Independent Director
Gerald Storch
Independent Director
Karen Vousden
Independent Director
Phyllis Yale
Declaration Date
Dividend Per Share
Ex-Div Date
06/17/2021
Dividend USD 0.49
07/01/2021
03/01/2021
Dividend USD 0.49
03/31/2021
12/10/2020
Dividend USD 0.49
12/31/2020
09/10/2020
Dividend USD 0.45
10/01/2020
06/11/2020
Dividend USD 0.45
07/02/2020
03/02/2020
Dividend USD 0.45
04/02/2020
12/05/2019
Dividend USD 0.45
01/02/2020
09/11/2019
Dividend USD 0.41
10/03/2019
06/13/2019
Dividend USD 0.41
07/03/2019
03/07/2019
Dividend USD 0.41
04/04/2019
12/06/2018
Dividend USD 0.41
01/03/2019
09/12/2018
Dividend USD 0.4
10/04/2018
06/14/2018
Dividend USD 0.4
07/05/2018
03/01/2018
Dividend USD 0.4
04/05/2018
12/07/2017
Dividend USD 0.4
01/04/2018
09/13/2017
Dividend USD 0.39
10/05/2017
06/14/2017
Dividend USD 0.39
07/05/2017
03/03/2017
Dividend USD 0.39
04/05/2017
12/09/2016
Dividend USD 0.39
01/04/2017
08/04/2016
Dividend USD 0.38
10/05/2016
About BMY
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abraxane, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Reyataz and Sustiva Franchise. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.

Webull offers kinds of Bristol-Myers Squibb Co stock information, including NYSE:BMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BMY stock methods without spending real money on the virtual paper trading platform.